Zevra Therapeutics Financial Ratios
NASDAQ: ZVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zevra Therapeutics ratio analysis
Zevra Therapeutics earned a net margin of 78.2% in FY 2025, up from -446.9% a year earlier. Gross margin was 84.5% compared with a median of 89.3% over the prior 5 years. Return on equity reached 53.8%, meaning Zevra Therapeutics generated 0.54 dollars of profit for every dollar of shareholders' equity, an unusually high figure that often reflects a small equity base after share buybacks.
Debt-to-equity stood at 0.40 versus 1.50 the year before, and the current ratio was 5.68. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Zevra Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 6.18 | — | — | — | — | — | — | — | — | — |
| Price / sales | 4.33 | 16.83 | 8.46 | 15.58 | 9.05 | 3.36 | 0.95 | — | — | — |
| Price / book | 2.98 | 10.02 | 3.75 | 2.11 | 2.55 | — | — | — | — | — |
| Gross margin | 84.5% | 68.6% | 89.3% | 97.8% | 92.8% | — | 22.1% | — | — | — |
| Operating margin | -59.1% | -368.5% | -180.6% | -418.9% | 27.0% | -42.2% | -158.4% | — | — | — |
| Net margin | 78.2% | -446.9% | -167.7% | -263.5% | -29.9% | -96.0% | -191.0% | — | — | — |
| Free cash flow margin | -2.3% | -295.0% | -123.2% | -185.1% | 36.1% | -14.8% | -185.1% | — | — | — |
| Return on equity (ROE) | 53.8% | -266.0% | -74.4% | -35.6% | -8.4% | — | — | — | — | — |
| Return on assets (ROA) | 29.2% | -59.2% | -26.7% | -23.2% | -6.4% | -113.8% | -233.4% | -211.1% | -82.7% | -19.5% |
| Debt / equity | 0.40 | 1.50 | 0.08 | 0.00 | — | — | — | — | — | — |
| Current ratio | 5.68 | 2.53 | 1.18 | 7.72 | 27.20 | 1.11 | 1.28 | 1.98 | 3.99 | 11.19 |
| Revenue growth | 350.9% | -14.0% | 170.3% | -64.5% | 115.6% | 3.5% | — | — | — | — |